Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Net Cash Used Provided by Financing Activities?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Net Cash Used Provided by Financing Activities is 
-$475.3M (1Y -29.4% )

ALXN Stock Price & Net Cash Used Provided by Financing Activities

Net Cash Used Provided by Financing Activities for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Cash Used Provided by Financing Activities

chevron_right 2021 -$73.8M +368x
( +24.5% / year avg)
chevron_left 1995 -$200.0 T
vertical_align_top Peak $4.8B +5.68x *
vertical_align_bottom Bottom -$1.0B
arrow_drop_up # Up Years 13 13 of 27
years up.
arrow_drop_down # Down Years 14
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.12x the rate relative to it's net cash used provided by financing activities over the same period.
  • If ALXN grows it's stock at the same rate as it's net cash used provided by financing activities (+24.5%/year) , it's stock price will grow +894% and hit $972.75 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 13 years (0%) it's net cash used provided by financing activities were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Net Cash Used Provided by Financing Activities Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Net Cash Used Provided by Financing Activities YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $-73 -87.7% - -
    4/1/2020 $-597 -25.3% - -
    4/1/2019 $-800 102.9% - -
    4/1/2018 $-394 -39.7% - -
    4/1/2017 $-654 -36.0% - -
    4/1/2016 $-1,022 -121.3% - -
    4/1/2015 $4,789 7655.5% - -
    4/1/2014 $61 -3.4% - -
    4/1/2013 $63 -90.8% - -
    4/1/2012 $691 1545.1% - -
    4/1/2011 $42 302.9% - -
    4/1/2010 $10 117.3% - -
    4/1/2009 $4 -88.8% - -
    4/1/2008 $42 -78.1% - -
    4/1/2007 $195 105.6% - -
    4/1/2006 $95 42.8% - -
    4/1/2005 $66 -66.1% - -
    4/1/2004 $196 342.7% - -
    4/1/2003 $44 21605.5% - -
    4/1/2002 $0 -99.9% - -
    4/1/2001 $314 90.3% - -
    4/1/2000 $165 1584.4% - -
    4/1/1999 $9 -62.6% - -
    4/1/1998 $26 -29.8% - -
    4/1/1997 $37 103.8% - -
    4/1/1996 $18 -9250.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Cash flow from financing activities (CFF) is a section of a company’s cash flow statement, which shows the net flows of cash that are used to fund the company. Financing activities include transactions involving debt, equity, and dividends.

    Cash flow from financing activities provides investors with insight into a company’s financial strength and how well a company's capital structure is managed.

    For more detailed definitions, please see Investopedia.